HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhou, Junmin ^a   Chen, Xianghong ^a   Gilvary, Danielle L ^a   Tejera, Melba M ^a   Eksioglu, Erika A ^a   Wei, Sheng ^a   Djeu, Julie Y ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; HIGH MOBILITY GROUP B1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CLUSTERIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

EID: 84945217231     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15085     Document Type: Article

References (53)

1. Borst, P., Jonkers, J. and Rottenberg, S. What makes tumors multidrug resistant? Cell cycle 6, 2782-2787 (2007).
2. Patterson, S. G. et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25, 6113-6122 (2006).
3. Zhong, B. et al. Induction of clusterin by AKT- role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 9, 1831-1841 (2010).
4. Parczyk, K., Pilarsky , C., Rachel, U. and Koch-Brandt, C. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120, 186-188 (1994).
5. Steinberg, J. et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3, 1707-1711 (1997).
6. Redondo, M. et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 157, 393-399 (2000).
7. Xie, D. et al. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103, 277-283 (2005).
8. Pucci, S. et al. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23, 2298-2304 (2004).
9. Watari, H. et al. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol 108, 527-532 (2008).
10. Mourra, N. et al. Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours. Histopathology 50, 331-337 (2007).
11. Lau, S. H. et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25, 1242-1250 (2006).
12. Lourda, M., Trougakos, I. P. and Gonos, E. S. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. International journal of cancer Journal international du cancer 120, 611-622 (2007).
13. Zhang, H. et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7, 909-915 (2005).
14. Liu, T. et al. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. European journal of cancer 45, 1846-1854 (2009).
15. Miyake, H. et al. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Molecular urology 5, 105-111 (2001).
16. Sallman, D. A. et al. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 6, 2938-2947 (2007).
17. Sensibar, J. A. et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer research 55, 2431-2437 (1995).
18. Goetz, E. M. et al. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene 30, 3745-3754 (2011).
19. Trougakos, I. P. et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res 15, 48-59 (2009).
20. Chi, K. N. et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97, 1287-1296 (2005).
21. Chi, K. N. et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28, 4247-4254 (2010).
22. Laskin, J. J. et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 7, 579-586 (2012).
23. Kang, R. et al. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19, 4046-4057 (2013).
24. Yang, H., Antoine, D. J., Andersson, U. and Tracey, K. J. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of leukocyte biology 93, 865-873 (2013).
25. Harris, H. E., Andersson, U. and Pisetsky, D. S. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8, 195-202 (2012).
26. Goodwin, G. H. and Johns, E. W. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. Eur J Biochem 40, 215-219 (1973).
27. Thomas, J. O. and Travers, A. A. HMG1 and 2, and related architectural DNA-binding proteins. Trends Biochem Sci 26, 167-174 (2001).
28. Bustin, M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19, 5237-5246 (1999).
29. Ueda, T. and Yoshida, M. HMGB proteins and transcriptional regulation. Biochim Biophys Acta 1799, 114-118 (2010).
30. Scaffidi, P., Misteli, T. and Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
31. Yang, H. et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107, 11942-11947 (2010).
32. Sha, Y., Zmijewski, J., Xu, Z. and Abraham, E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180, 2531-2537 (2008).
33. Urbonaviciute, V. et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205, 3007-3018 (2008).
34. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-496 (2007).
35. Yang, D. et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. Journal of leukocyte biology 81, 59-66 (2007).
36. Degryse, B. et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152, 1197-1206 (2001).
37. Mitola, S. et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176, 12-15 (2006).
38. Limana, F. et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 97, e73-83 (2005).
39. Kuniyasu, H. et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196, 163-170 (2002).
40. Srikrishna, G. and Freeze, H. H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11, 615-628 (2009).
41. Sims, G. P. et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28, 367-388 (2010).
42. Brezniceanu, M. L. et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. Faseb J 17, 1295-1297 (2003).
43. Poser, I., Golob, M., Buettner, R. and Bosserhoff, A. K. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Molecular and cellular biology 23, 2991-2998 (2003).
44. Choi, Y. R. et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer research 63, 2188-2193 (2003).
45. Kuniyasu, H., Chihara, Y. and Takahashi, T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10, 445-448 (2003).
46. Yang, G. L. et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 106, 57-61 (2012).
47. Wild, C. A. et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48, 409-416 (2012).
48. Maeda, S. et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 360, 394-400 (2007).
49. Gonzalez-Reyes, S. et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC cancer 10, 665 (2010).
50. Huttunen, H. J. et al. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research 62, 4805-4811 (2002).
51. Huang, J. et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8, 275-277 (2012).
52. Liu, L. et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 25, 23-31 (2011).
53. Zhang, F. et al. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nature communications 5, 5775 (2014).